1. Home
  2. DHIL vs AURA Comparison

DHIL vs AURA Comparison

Compare DHIL & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamond Hill Investment Group Inc.

DHIL

Diamond Hill Investment Group Inc.

HOLD

Current Price

$174.99

Market Cap

463.8M

Sector

Finance

ML Signal

HOLD

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$8.32

Market Cap

419.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHIL
AURA
Founded
1990
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
419.5M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
DHIL
AURA
Price
$174.99
$8.32
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.00
AVG Volume (30 Days)
15.8K
284.3K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
3.43%
N/A
EPS Growth
14.37
N/A
EPS
17.91
N/A
Revenue
$145,201,729.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.77
N/A
Revenue Growth
6.69
N/A
52 Week Low
$114.11
$4.73
52 Week High
$175.00
$7.68

Technical Indicators

Market Signals
Indicator
DHIL
AURA
Relative Strength Index (RSI) 70.47 71.58
Support Level $171.71 $6.00
Resistance Level N/A N/A
Average True Range (ATR) 0.60 0.44
MACD 0.25 0.03
Stochastic Oscillator 99.72 90.77

Price Performance

Historical Comparison
DHIL
AURA

About DHIL Diamond Hill Investment Group Inc.

Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: